Ewing sarcoma (ES) is a rare and aggressive cancer that primarily affects bones or soft tissue, commonly occurring in children and young adults. It affects approximately 2.1 per million children globally and is the second most prevalent bone sarcoma after osteosarcoma. There is a significant unmet clinical need for better therapies, as current treatment options, such as chemotherapy, surgery, and radiation, have limited long-term efficacy. The increasing focus on targeted therapies and novel Ewing sarcoma drug candidates is driving pipeline expansion.
Major companies involved in the Ewing sarcoma pipeline drugs market include Eli Lilly and Company, Pfizer, and others.
Leading drugs currently in the pipeline include Vincristine-Topotecan-Cyclophosphamide, Abemaciclib, Seclidemstat, and others.
Advancements in targeted therapies and precision medicine, coupled with growing clinical trials and research investments, are driving the growth of Ewing sarcoma drug pipeline to address significant unmet medical needs.
The Ewing Sarcoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Ewing sarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Ewing sarcoma. The Ewing sarcoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Ewing sarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Ewing sarcoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Ewing sarcoma.
Ewing Sarcoma is a rare and aggressive cancer that primarily affects bones or soft tissues in children and young adults. It occurs when abnormal cells appear in the bones or cartilage, often in the pelvis, thigh, or chest area. The exact cause is unknown, however, it involves genetic mutations, including a fusion of the EWSR1 gene with other genes.
Ewing Sarcoma treatment typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery aims to eliminate the tumor, while chemotherapy targets cancer cells throughout the body. Radiation may be utilized for tumors that cannot be surgically removed. Treatment plans can be customized based on the tumor's location and stage.
Ewing sarcoma has an incidence of 2.1 cases per million children worldwide, making it the second most common bone sarcoma after osteosarcoma. In the United States, the estimated incidence is 2.9 cases per million children, accounting for 10%-15% of malignant bone tumors and 3% of all pediatric cancers. In the United Kingdom, approximately 90 new cases are diagnosed annually, while in India, Ewing sarcoma represents 3%-4% of cancers in children aged 0-14 years.
This section of the report covers the analysis of Ewing sarcoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Ewing sarcoma clinical trials.
The drug molecule categories covered under the Ewing sarcoma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, gene therapies, RNA-based therapies, and others. The Ewing sarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Ewing sarcoma.
The EMR report for the Ewing sarcoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Ewing sarcoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Ewing sarcoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Ewing sarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Ewing sarcoma drug candidates.
Vincristine, topotecan, and cyclophosphamide are chemotherapy drugs that target rapidly dividing cancer cells, playing key roles in treating various cancers, including Ewing sarcoma. The Phase 3 clinical trial sponsored by the Children's Oncology Group is investigating how the combination of these three drugs, in addition to the standard chemotherapy regimen, affects event-free and overall survival in children and young adults with localized Ewing sarcoma.
Abemaciclib is a small molecule inhibitor targeting CDK4 and CDK6, which play a crucial role in regulating the cell cycle. A Phase 2 study, sponsored by Eli Lilly and Company, aims to assess the efficacy of adding Abemaciclib to chemotherapy for relapsed or refractory Ewing's sarcoma. This trial seeks to improve treatment outcomes in patients who have not responded to standard therapies.
Seclidemstat (SP-2577), is a novel, oral, reversible LSD1 inhibitor being investigated in a Phase 1 clinical trial sponsored by Salarius Pharmaceuticals. The objective of this study is to evaluate the safety and efficacy of Seclidemstat, both as a single agent and in combination with topotecan and cyclophosphamide, in patients with relapsed or refractory Ewing sarcoma and selected sarcomas. This drug offers the potential for treating sarcomas with limited therapeutic options.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Ewing Sarcoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Ewing sarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Ewing sarcoma collaborations, regulatory environments, and potential growth opportunities.
Global Cancer Screening Market
Global Cancer Tumor Profiling Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share